{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:07:21Z","timestamp":1791295641826,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,2,9]],"date-time":"2018-02-09T00:00:00Z","timestamp":1518134400000},"content-version":"vor","delay-in-days":1135,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100007801","name":"Fundaci\u00f3n S\u00e9neca","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007801","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Ministerio de Sanidad"},{"name":"National Network of Investigation in Cardiovascular Diseases"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Heart Failure"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.jchf.2014.07.015","type":"journal-article","created":{"date-parts":[[2014,11,12]],"date-time":"2014-11-12T05:22:12Z","timestamp":1415769732000},"page":"50-58","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":91,"title":["Mineralocorticoid Receptor Antagonists Modulate Galectin-3 and Interleukin-33\/ST2 Signaling in Left Ventricular Systolic\u00a0Dysfunction After Acute\u00a0Myocardial Infarction"],"prefix":"10.1016","volume":"3","author":[{"given":"Antonio","family":"Lax","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus","family":"Sanchez-Mas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria C.","family":"Asensio-Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria J.","family":"Fernandez-Del Palacio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Caballero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris P.","family":"Garrido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco J.","family":"Pastor-Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L.","family":"Januzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domingo A.","family":"Pascual-Figal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchf.2014.07.015_bib1","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of\u00a0spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2014.07.015_bib2","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2014.07.015_bib3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2014.07.015_bib4","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1161\/01.CIR.102.22.2700","article-title":"Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the Randomized Aldactone Evaluation Study (RALES). Rales Investigators","volume":"102","author":"Zannad","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2014.07.015_bib5","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0735-1097(01)01116-0","article-title":"Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure","volume":"37","author":"Tsutamoto","year":"2001","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2014.07.015_bib6","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/MNH.0b013e3282f56854","article-title":"Mechanisms of mineralocorticoid receptor-mediated cardiac fibrosis and vascular inflammation","volume":"17","author":"Young","year":"2008","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.jchf.2014.07.015_bib7","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1177\/1074248410387606","article-title":"Aldosterone Antagonists in Heart Failure","volume":"16","author":"Guglin","year":"2010","journal-title":"J\u00a0Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.jchf.2014.07.015_bib8","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/ejhf.31","article-title":"Selection of a mineralocorticoid receptor antagonist for patients with hypertension or heart failure: Comparison of spironolactone and eplerenone","volume":"16","author":"Iqbal","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2014.07.015_bib9","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/eurheartj\/ehs104","volume":"33","author":"McMurray","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2014.07.015_bib10","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2014.07.015_bib11","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.cll.2013.11.009","article-title":"Soluble ST2 and Galectin-3 in Heart Failure","volume":"34","author":"Shah","year":"2014","journal-title":"Clin Lab Med"},{"key":"10.1016\/j.jchf.2014.07.015_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11897-010-0004-x","article-title":"Galectin-3 in cardiac remodeling and heart failure","volume":"7","author":"De Boer","year":"2010","journal-title":"Curr Heart Fail"},{"key":"10.1016\/j.jchf.2014.07.015_bib13","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1172\/JCI30634","article-title":"IL-33 and ST2 comprise a\u00a0critical biomechanically induced and cardioprotective signaling system","volume":"117","author":"Sanada","year":"2007","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jchf.2014.07.015_bib14","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/nrd2660","article-title":"The IL-33\/ST2 pathway: therapeutic target and novel biomarker","volume":"7","author":"Kakkar","year":"2008","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jchf.2014.07.015_bib15","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00392-012-0500-y","article-title":"Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure","volume":"102","author":"Lok","year":"2013","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.jchf.2014.07.015_bib16","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jacc.2012.04.053","article-title":"Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community","volume":"60","author":"Ho","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2014.07.015_bib17","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1161\/01.CIR.0000127958.21003.5A","article-title":"Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction","volume":"109","author":"Shimpo","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2014.07.015_bib18","first-page":"65","article-title":"Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly-sensitive troponin T measurements in patients with chronic heart failure","volume":"2","author":"Gaggin","year":"2014","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jchf.2014.07.015_bib19","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1161\/CIRCHEARTFAILURE.113.000207","article-title":"Soluble ST2 in ambulatory patients with heart failure: association with functional capacity and long-term outcomes","volume":"6","author":"Felker","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2014.07.015_bib20","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1161\/CIRCULATIONAHA.112.129437","article-title":"Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study","volume":"126","author":"Wang","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2014.07.015_bib21","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.cardfail.2013.11.011","article-title":"Relationship between Galectin-3 Levels and mineralocorticoid receptor antagonist use in heart failure: analysis from the HF-ACTION study","volume":"20","author":"Fiuzat","year":"2014","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.jchf.2014.07.015_bib22","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jacc.2013.07.087","article-title":"Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3","volume":"63","author":"Bayes-Genis","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2014.07.015_bib23","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jacc.2009.08.047","article-title":"Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction","volume":"55","author":"Weir","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2014.07.015_bib24","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1161\/CIRCHEARTFAILURE.112.000146","article-title":"Galectin-3 and cardiac function in survivors of\u00a0acute myocardial infarction","volume":"6","author":"Weir","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2014.07.015_bib25","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1161\/CIRCHEARTFAILURE.112.971168","article-title":"Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis","volume":"6","author":"Yu","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2014.07.015_bib26","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1161\/01.CIR.0000147181.65298.4D","article-title":"Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction","volume":"110","author":"Sharma","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2014.07.015_bib27","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1016\/j.bcp.2008.02.003","article-title":"14-3-3 protein regulates Ask1 signaling and protects against diabetic cardiomyopathy","volume":"75","author":"Thandavarayan","year":"2008","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jchf.2014.07.015_bib28","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1161\/01.CIR.0000038705.69871.D9","article-title":"Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction","volume":"106","author":"Weinberg","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2014.07.015_bib29","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1161\/CIRCHEARTFAILURE.109.873240","article-title":"Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling","volume":"2","author":"Seki","year":"2009","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2014.07.015_bib30","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1161\/HYPERTENSIONAHA.111.190512","article-title":"Aldosterone inhibits antifibrotic factors in mouse hypertensive heart","volume":"59","author":"Azibani","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.jchf.2014.07.015_bib31","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1161\/ATVBAHA.112.300569","article-title":"Galectin-3 mediates aldosterone-induced vascular fibrosis","volume":"33","author":"Calvier","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jchf.2014.07.015_bib32","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1016\/j.jacc.2003.05.003","article-title":"Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction","volume":"42","author":"Fraccarollo","year":"2003","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2014.07.015_bib33","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1161\/CIRCULATIONAHA.110.983023","article-title":"Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction","volume":"123","author":"Fraccarollo","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2014.07.015_bib34","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1067\/mhj.2001.111258","article-title":"Aldosterone inhibition limits collagen synthesis and progressive left ventricular enlargement after\u00a0anterior myocardial infarction","volume":"141","author":"Modena","year":"2001","journal-title":"Am Heart J"},{"key":"10.1016\/j.jchf.2014.07.015_bib35","doi-asserted-by":"crossref","first-page":"H404","DOI":"10.1152\/ajpheart.00747.2008","article-title":"N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by\u00a0galectin-3, a mammalian adhesion\/growth-regulatory lectin","volume":"296","author":"Liu","year":"2009","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.jchf.2014.07.015_bib36","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1291\/hypres.27.781","article-title":"Pleiotropic actions of aldosterone and the effects of eplerenone, a selective mineralocorticoid receptor antagonist","volume":"27","author":"Takeda","year":"2004","journal-title":"Hypertens Res"},{"key":"10.1016\/j.jchf.2014.07.015_bib37","first-page":"779","article-title":"Differential actions of eplerenone and spironolactone on the protective effect of testosterone against cardiomyocyte apoptosis in\u00a0vitro","volume":"63","author":"Sanchez-Mas","year":"2010","journal-title":"Rev Esp Cardiol"},{"key":"10.1016\/j.jchf.2014.07.015_bib38","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.1016\/j.ijcard.2013.06.103","article-title":"Spironolactone in mild chronic heart failure: insights from a propensity-matched analysis of the\u00a0MUSIC study cohort","volume":"168","author":"Pascual-Figal","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jchf.2014.07.015_bib39","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1161\/CIRCHEARTFAILURE.112.000115","article-title":"Association of spironolactone use with all-cause mortality in heart failure: a propensity scored cohort study","volume":"6","author":"Lund","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2014.07.015_bib40","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1016\/j.jacc.2011.04.049","volume":"58","author":"Rossignol","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2014.07.015_bib41","doi-asserted-by":"crossref","first-page":"643","DOI":"10.12659\/AOT.889396","article-title":"Local expression of myocardial galectin-3 does not\u00a0correlate with its serum levels in patients undergoing heart transplantation","volume":"18","author":"Beiras-Fernandez","year":"2013","journal-title":"Ann Transplant"},{"key":"10.1016\/j.jchf.2014.07.015_bib42","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1161\/CIRCHEARTFAILURE.113.000457","article-title":"Soluble concentrations of the interleukin receptor family member ST2 and \u03b2-blocker therapy in chronic heart failure","volume":"6","author":"Gaggin","year":"2013","journal-title":"Circ Heart Fail"}],"container-title":["JACC: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177914003874?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177914003874?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T04:49:20Z","timestamp":1761972560000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213177914003874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S2213177914003874"],"URL":"https:\/\/doi.org\/10.1016\/j.jchf.2014.07.015","relation":{},"ISSN":["2213-1779"],"issn-type":[{"value":"2213-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mineralocorticoid Receptor Antagonists Modulate Galectin-3 and Interleukin-33\/ST2 Signaling in Left Ventricular Systolic\u00a0Dysfunction After Acute\u00a0Myocardial Infarction","name":"articletitle","label":"Article Title"},{"value":"JACC: Heart Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2014.07.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}